<document>

<filing_date>
2018-03-27
</filing_date>

<publication_date>
2020-12-03
</publication_date>

<priority_date>
2017-03-27
</priority_date>

<ipc_classes>
A61K31/7125,C12Q1/6811,C12Q1/6886
</ipc_classes>

<assignee>
CARIS SCIENCE
</assignee>

<inventors>
SPETZLER, DAVID
DOMENYUK, VALERIY
MIGLARESE, MARK
Liu, Xianghua
</inventors>

<docdb_family_id>
63676936
</docdb_family_id>

<title>
OLIGONUCLEOTIDE PROBES AND USES THEREOF
</title>

<abstract>
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include circulating biomarkers such as micro vesicles, including those derived from various diseases.
</abstract>

<claims>
1. An oligonucleotide comprising a sequence according to any one of SEQ ID NOs 4151-14156.
2. An oligonucleotide comprising a sequence according to any sequence in Table 44.
3. An oligonucleotide consisting of a sequence according to any sequence in Table 44.
4. The oligonucleotide of claim 3, further comprising a 5′ region and/or a 3′ region flanking the sequence according to any sequence in Table 44.
5. An oligonucleotide comprising a sequence according to any one of the SEQ ID NOs in any preceding claim and further having a 5′ region with sequence 5′-CTAGCATGACTGCAGTACGT (SEQ ID NO. 131) and/or a 3′ region with sequence 5′-CTGTCTCTTATACACATCTGACGCTGCCGACGA (SEQ ID NO. 132).
6. An oligonucleotide comprising a nucleic acid sequence or a portion thereof that is at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100 percent homologous to an oligonucleotide sequence according to any preceding claim.
7. A plurality of oligonucleotides comprising at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or at least 10000 different oligonucleotide sequences according to claim 6.
8. The oligonucleotide or the plurality of oligonucleotides according to any preceding claim, wherein the oligonucleotide or the plurality of oligonucleotides comprises a DNA, RNA, 2′-O-methyl backbone, phosphorothioate backbone, or any combination thereof.
9. The oligonucleotide or the plurality of oligonucleotides according to any preceding claim, wherein the oligonucleotide or the plurality of oligonucleotides comprises at least one of DNA, RNA, PNA, LNA, UNA, and any combination thereof.
10. The oligonucleotide or the plurality of oligonucleotides according to any preceding claim, wherein the oligonucleotide or the plurality of oligonucleotides comprises at least one functional modification selected from the group consisting of biotinylation, a non-naturally occurring nucleotide, a deletion, an insertion, an addition, and a chemical modification.
11. The oligonucleotide or plurality of oligonucleotides according to claim 10, wherein the chemical modification comprises at least one of C18, polyethylene glycol (PEG), PEG4, PEG6, PEG8, PEG12, and an SM(PEG)n crosslinker.
12. The oligonucleotide or plurality of oligonucleotides according to any preceding claim, wherein the oligonucleotide or plurality of oligonucleotides is labeled.
13. The oligonucleotide or plurality of oligonucleotides according to any preceding claim, wherein the oligonucleotide or plurality of oligonucleotides is attached to a nanoparticle, liposome, gold, magnetic label, fluorescent label, light emitting particle, radioactive label, or a combination thereof.
14. A method of enriching an oligonucleotide library comprising a plurality of oligonucleotides, the method comprising: (a) performing at least one round of positive selection, wherein the positive selection comprises: (i) contacting at least one sample with the plurality of oligonucleotides, wherein the at least one sample is from a single patient; and (ii) recovering members of the plurality of oligonucleotides that associated with the at least one sample; (b) optionally performing at least one round of negative selection, wherein the negative selection comprises: (i) contacting at least one additional sample with the plurality of oligonucleotides, wherein at least one additional sample is from an additional single patient; and (ii) recovering members of the plurality of oligonucleotides that did not associate with the at least one additional sample; and (c) amplifying the members of the plurality of oligonucleotides recovered in at least one or step (a)(ii) and step (b)(ii), thereby enriching the oligonucleotide library.
15. The method of claim 14, wherein the recovered members of the plurality of oligonucleotides in step (a)(ii) are used as the input for the next iteration of step (a)(i).
16. The method of claim 14 or 15, wherein the recovered members of the plurality of oligonucleotides in step (b)(ii) are used as the input for the next iteration of step (a)(i).
17. The method of any one of claims 14-16, wherein the at least one sample is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 samples.
18. The method of any one of claims 14-17, wherein the at least one additional sample is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 samples.
19. The method of any one of claims 14-18, wherein the unenriched oligonucleotide library comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 106, 107, 108, 109, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, or at least 1018 different oligonucleotide sequences.
20. The method of any one of claims 14-19, wherein the unenriched oligonucleotide library comprises a naïve F-Trin library.
21. The method of any one of claims 14-20, wherein the at least one sample is from a same single patient in multiple iterations of positive selection.
22. The method of any one of claims 14-20, wherein the at least one sample is from a same single patient in at least one repetition of positive selection and is from a different single patient in at least one other iteration of positive selection.
23. The method of any one of claims 14-22, wherein the at least one additional sample is from a same additional single patient in multiple iterations of negative selection.
24. The method of any one of claims 14-22, wherein the at least one additional sample is from a same additional single patient in at least one repetition of negative selection and is from a different additional single patient in other at least one iteration of negative selection.
25. A method of characterizing a phenotype in a sample comprising: (a) contacting the sample with at least one oligonucleotide or plurality of oligonucleotides according to any preceding claim; and (b) identifying a presence or level of a complex formed between the at least one oligonucleotide or plurality of oligonucleotides and the sample, wherein the presence or level is used to characterize the phenotype.
26. The method of claim 25, wherein the identifying comprises sequencing, amplification, hybridization, gel electrophoresis or chromatography.
27. The method of claim 26, wherein the identifying by hybridization comprises contacting the sample with at least one labeled probe that is configured to hybridize with at least one oligonucleotide.
28. The method of claim 27, wherein the at least one labeled probe is directly or indirectly attached to a label.
29. The method of claim 28, wherein the label comprises a fluorescent or magnetic label.
30. The method of claim 26, wherein the sequencing comprises next generation sequencing, dye termination sequencing, and/or pyrosequencing.
31. The method of any one of claims 25-30, wherein the at least one oligonucleotide comprises an oligonucleotide or plurality of oligonucleotides according to any one of claims 1-13.
32. The method of any one of claims 25-31, wherein the at least one oligonucleotide comprises an oligonucleotide or plurality of oligonucleotides from a library enriched according to any one of claims 14-24.
33. The method of any one of claims 25-32, wherein the phenotype comprises a disease or disorder.
34. The method of claim 33, wherein the characterizing comprises a diagnosis, prognosis and/or theranosis for the disease or disorder.
35. The method of claim 34, wherein the theranosis comprises predicting a treatment efficacy or lack thereof, or monitoring a treatment efficacy.
36. The method of any one of claims 25-35, wherein the complex formed between the at least one oligonucleotide or plurality of oligonucleotides and the sample comprises a complex formed between a microvesicle population in the sample and the at least one oligonucleotide or plurality of oligonucleotides.
37. The method of claim 36, wherein the microvesicle population is isolated before or after the contacting using affinity purification, filtration, polymer precipitation, PEG precipitation, F68, ultracentrifugation, a molecular crowding reagent, affinity isolation, affinity selection, or any combination thereof.
38. The method of any one of claims 25-37 wherein the characterizing comprises comparing the presence or level to a reference.
39. The method of claim 38, wherein the reference comprises the presence or level determined in a sample from an individual without a disease or disorder, or from an individual with a different state of a disease or disorder.
40. The method of claim 38 or 39, wherein the comparison to the reference of at least one oligonucleotide comprising at least one sequence according to any one of claims 1-7 indicates that the sample comprises a cancer sample or a non-cancer/normal sample.
41. The method of any one of claims 25-40, wherein the sample comprises a bodily fluid, tissue sample or cell culture.
42. The method of claim 41, wherein the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair oil, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or umbilical cord blood.
43. The method any one of claims 25-42, wherein the sample is from a subject suspected of having or being predisposed to a disease or disorder.
44. The method of any of claims 31-43, wherein the disease or disorder comprises a cancer, a premalignant condition, an inflammatory disease, an immune disease, an autoimmune disease or disorder, a cardiovascular disease or disorder, neurological disease or disorder, infectious disease or pain.
45. The method of claim 44, wherein the cancer comprises an acute lymphoblastic leukemia; acute myeloid leukemia; adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal cancer; appendix cancer; astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem glioma; brain tumor (including brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma); breast cancer; bronchial tumors; Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma of unknown primary site; central nervous system atypical teratoid/rhabdoid tumor; central nervous system embryonal tumors; cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia; chronic myelogenous leukemia; chronic myeloproliferative disorders; colon cancer; colorectal cancer; craniopharyngioma; cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial cancer; ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing sarcoma; extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile duct cancer; gallbladder cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor; gastrointestinal stromal cell tumor; gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor; glioma; hairy cell leukemia; head and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer; intraocular melanoma; islet cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis; laryngeal cancer; lip cancer; liver cancer; lung cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma; medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma; metastatic squamous neck cancer with occult primary; mouth cancer; multiple endocrine neoplasia syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer; neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors; ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential tumor; pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer; penile cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate differentiation; pineoblastoma; pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; primary central nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer; renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma; rhabdomyosarcoma; salivary gland cancer; Sézary syndrome; small cell lung cancer; small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer; thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma; vaginal cancer; vulvar cancer; Waldenström macroglobulinemia; or Wilm's tumor.
46. The method of claim 44, wherein the cancer comprises a breast cancer, wherein optionally the breast cancer comprises a lobular, ductal or triple negative breast cancer.
47. The method of claim 44, wherein the cancer comprises a lobular breast cancer.
48. The method of claim 44, wherein the premalignant condition comprises Barrett's Esophagus.
49. The method of claim 44, wherein the autoimmune disease comprises inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune hepatitis, multiple sclerosis, myasthenia gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic lupus erythematosis (SLE), Hashimoto's Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens Disease, CREST syndrome, Scleroderma, Rheumatic Disease, organ rejection, Primary Sclerosing Cholangitis, or sepsis.
50. The method of claim 44, wherein the cardiovascular disease comprises atherosclerosis, congestive heart failure, vulnerable plaque, stroke, ischemia, high blood pressure, stenosis, vessel occlusion or a thrombotic event.
51. The method of claim 44, wherein the neurological disease comprises Multiple Sclerosis (MS), Parkinson's Disease (PD), Alzheimer's Disease (AD), schizophrenia, bipolar disorder, depression, autism, Prion Disease, Pick's disease, dementia, Huntington disease (HD), Down's syndrome, cerebrovascular disease, Rasmussen's encephalitis, viral meningitis, neurospsychiatric systemic lupus erythematosus (NPSLE), amyotrophic lateral sclerosis, Creutzfeldt-Jacob disease, Gerstmann-Straussler-Scheinker disease, transmissible spongiform encephalopathy, ischemic reperfusion damage (e.g. stroke), brain trauma, microbial infection, or chronic fatigue syndrome.
52. The method of claim 44, wherein the pain comprises fibromyalgia, chronic neuropathic pain, or peripheral neuropathic pain.
53. The method of claim 44, wherein the infectious disease comprises a bacterial infection, viral infection, yeast infection, Whipple's Disease, Prion Disease, cirrhosis, methicillin-resistant Staphylococcus aureus, HIV, HCV, hepatitis, syphilis, meningitis, malaria, tuberculosis, influenza.
54. A kit comprising a reagent for carrying out the method of any of claims 25-53.
55. Use of a reagent for carrying out the method of any of claims 25-53.
56. The kit of claim 54 or use of claim 55, wherein the reagent comprises an oligonucleotide or a plurality of oligonucleotides according to any one of claims 1-13.
57. A method of imaging at least one cell or tissue, comprising contacting the at least one cell or tissue with at least one oligonucleotide or plurality of oligonucleotides according to any one of claims 1-13, and detecting the at least one oligonucleotide or the plurality of oligonucleotides in contact with at least one cell or tissue.
58. The method of claim 57, wherein the at least one oligonucleotide or the plurality of oligonucleotides is according to claim 12 or 13.
59. The method of claim 57 or 58, wherein the at least one oligonucleotide or the plurality of oligonucleotides is administered to a subject prior to the detecting.
60. The method any one of claims 57-59, wherein the at least one cell or tissue is from a subject suspected of having or being predisposed to a disease or disorder.
61. The method of any one of claims 57-60, wherein the at least one cell or tissue comprises neoplastic, malignant, tumor, hyperplastic, or dysplastic cells.
62. The method of any one of claims 57-60, wherein the at least one cell or tissue comprises lymphoma, leukemia, renal carcinoma, sarcoma, hemangiopericytoma, melanoma, abdominal cancer, gastric cancer, colon cancer, cervical cancer, prostate cancer, pancreatic cancer, breast cancer, or non-small cell lung cancer cells.
63. A pharmaceutical composition comprising a therapeutically effective amount of the at least one oligonucleotide or the plurality of oligonucleotides according to any one of 1-13, or a salt thereof, and a pharmaceutically acceptable carrier, diluent, or both.
64. The pharmaceutical composition of claim 63, wherein the at least one oligonucleotide or the plurality of oligonucleotides is attached to a toxin or chemotherapeutic agent.
65. The pharmaceutical composition of claim 63, wherein the at least one oligonucleotide or the plurality of oligonucleotides is attached to a liposome or nanoparticle.
66. The pharmaceutical composition of claim 65, wherein the liposome or nanoparticle comprises a small molecule, drug, toxin or chemotherapeutic agent.
67. A method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering the composition of any of claims 63-66 to the subject.
68. A method of inducing cytotoxicity in a subject, comprising administering the composition of any of claims 63-66 to the subject.
69. A method comprising detecting a transcript or protein in a biological sample from a subject, comparing a presence or level of the transcript to a reference, and administering the composition of any of claims 63-66 to the subject based on the comparison.
70. The method of any one of claims 67-69, wherein the administering comprises at least one of intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, topical administration, or any combination thereof.
71. A nanoparticle conjugated to the at least one oligonucleotide or the plurality of oligonucleotides according to any one of claims 1-13.
72. The nanoparticle of claim 71, wherein the nanoparticle comprises a small molecule, drug, toxin or chemotherapeutic agent.
73. The nanoparticle of claim 71 or claim 72, wherein the nanoparticle is ≤100 nm in diameter.
74. A pharmaceutical composition comprising a therapeutically effective amount of the nanoparticle of claim 71 or claim 72, and a pharmaceutically acceptable carrier, diluent, or both.
75. A method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering the pharmaceutical composition of claim 74 to the subject.
76. A method of inducing cytotoxicity in a subject, comprising administering the pharmaceutical composition of claim 74 to the subject.
77. A method comprising detecting a transcript or protein in a biological sample from a subject, comparing a presence or level of the transcript to a reference, and administering the pharmaceutical composition of claim 74 to the subject based on the comparison.
78. The method of any one of claims 75-77, wherein the administering comprises at least one of intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, topical administration, or any combination thereof.
79. A method of characterizing a phenotype in a sample comprising: (a) detecting at least one microRNA in the sample, wherein the at least one microRNA is listed in Table 45 or Table 46; and (b) identifying a presence or level of the at least one the sample, wherein the presence or level is used to characterize the phenotype.
80. The method of claim 79, wherein the at least one microRNA comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 microRNA listed in Table 45.
81. The method of claim 79, wherein the at least one microRNA comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 microRNA listed in Table 46.
82. The method of any one of claims 79-81, wherein the identifying comprises sequencing, amplification, hybridization, gel electrophoresis or chromatography.
83. The method of any one of claims 79-82, wherein the at least one microRNA comprises miR-1299.
84. The method of any one of claims 79-83, wherein the at least one microRNA is isolated from a protein complex, wherein optionally the protein complex comprises an Argonaut protein, Ago2 Ago1, Ago3, Ago4, or GW182.
85. The method of claim 84, wherein the protein complex comprises Ago2.
86. The method of any one of claims 79-85, wherein the phenotype comprises a disease or disorder.
87. The method of claim 86, wherein the characterizing comprises a diagnosis, prognosis and/or theranosis for the disease or disorder.
88. The method of claim 87, wherein the theranosis comprises predicting a treatment efficacy or lack thereof, or monitoring a treatment efficacy.
89. The method of any one of claims 79-88, wherein the at least one microRNA is associated with a microvesicle population.
90. The method of claim 89, wherein the microvesicle population is isolated from the sample using affinity purification, filtration, polymer precipitation, PEG precipitation, F68, ultracentrifugation, a molecular crowding reagent, affinity isolation, affinity selection, or any combination thereof.
91. The method of any one of claims 79-90, wherein the characterizing comprises comparing the presence or level to a reference.
92. The method of claim 91, wherein the reference comprises the presence or level determined in a sample from an individual without a disease or disorder, or from an individual with a different state of a disease or disorder.
93. The method of any one of claims 79-92, wherein the sample comprises a bodily fluid, tissue sample or cell culture.
94. The method of claim 93, wherein the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair oil, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or umbilical cord blood.
95. The method any one of claims 79-94, wherein the sample is from a subject suspected of having or being predisposed to a disease or disorder.
96. The method of any of claims 33-34, 43-44, 60, 67, 75, or 86-95, wherein the disease or disorder comprises a cancer, a premalignant condition, an inflammatory disease, an immune disease, an autoimmune disease or disorder, a cardiovascular disease or disorder, neurological disease or disorder, infectious disease or pain.
97. The method of claim 96, wherein the cancer comprises an acute lymphoblastic leukemia; acute myeloid leukemia; adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; anal cancer; appendix cancer; astrocytomas; atypical teratoid/rhabdoid tumor; basal cell carcinoma; bladder cancer; brain stem glioma; brain tumor (including brain stem glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma); breast cancer; bronchial tumors; Burkitt lymphoma; cancer of unknown primary site; carcinoid tumor; carcinoma of unknown primary site; central nervous system atypical teratoid/rhabdoid tumor; central nervous system embryonal tumors; cervical cancer; childhood cancers; chordoma; chronic lymphocytic leukemia; chronic myelogenous leukemia; chronic myeloproliferative disorders; colon cancer; colorectal cancer; craniopharyngioma; cutaneous T-cell lymphoma; endocrine pancreas islet cell tumors; endometrial cancer; ependymoblastoma; ependymoma; esophageal cancer; esthesioneuroblastoma; Ewing sarcoma; extracranial germ cell tumor; extragonadal germ cell tumor; extrahepatic bile duct cancer; gallbladder cancer; gastric (stomach) cancer; gastrointestinal carcinoid tumor; gastrointestinal stromal cell tumor; gastrointestinal stromal tumor (GIST); gestational trophoblastic tumor; glioma; hairy cell leukemia; head and neck cancer; heart cancer; Hodgkin lymphoma; hypopharyngeal cancer; intraocular melanoma; islet cell tumors; Kaposi sarcoma; kidney cancer; Langerhans cell histiocytosis; laryngeal cancer; lip cancer; liver cancer; lung cancer; malignant fibrous histiocytoma bone cancer; medulloblastoma; medulloepithelioma; melanoma; Merkel cell carcinoma; Merkel cell skin carcinoma; mesothelioma; metastatic squamous neck cancer with occult primary; mouth cancer; multiple endocrine neoplasia syndromes; multiple myeloma; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic syndromes; myeloproliferative neoplasms; nasal cavity cancer; nasopharyngeal cancer; neuroblastoma; Non-Hodgkin lymphoma; nonmelanoma skin cancer; non-small cell lung cancer; oral cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma; other brain and spinal cord tumors; ovarian cancer; ovarian epithelial cancer; ovarian germ cell tumor; ovarian low malignant potential tumor; pancreatic cancer; papillomatosis; paranasal sinus cancer; parathyroid cancer; pelvic cancer; penile cancer; pharyngeal cancer; pineal parenchymal tumors of intermediate differentiation; pineoblastoma; pituitary tumor; plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; primary central nervous system (CNS) lymphoma; primary hepatocellular liver cancer; prostate cancer; rectal cancer; renal cancer; renal cell (kidney) cancer; renal cell cancer; respiratory tract cancer; retinoblastoma; rhabdomyosarcoma; salivary gland cancer; Sézary syndrome; small cell lung cancer; small intestine cancer; soft tissue sarcoma; squamous cell carcinoma; squamous neck cancer; stomach (gastric) cancer; supratentorial primitive neuroectodermal tumors; T-cell lymphoma; testicular cancer; throat cancer; thymic carcinoma; thymoma; thyroid cancer; transitional cell cancer; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumor; ureter cancer; urethral cancer; uterine cancer; uterine sarcoma; vaginal cancer; vulvar cancer; Waldenström macroglobulinemia; or Wilm's tumor.
98. The method of claim 96, wherein the cancer comprises a breast cancer, wherein optionally the breast cancer comprises a lobular, ductal or triple negative breast cancer.
99. The method of claim 96, wherein the cancer comprises a lobular breast cancer.
100. The method of claim 96, wherein the cancer comprises prostate cancer.
101. The method of claim 96, wherein the premalignant condition comprises Barrett's Esophagus.
102. The method of claim 96, wherein the autoimmune disease comprises inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), pelvic inflammation, vasculitis, psoriasis, diabetes, autoimmune hepatitis, multiple sclerosis, myasthenia gravis, Type I diabetes, rheumatoid arthritis, psoriasis, systemic lupus erythematosis (SLE), Hashimoto's Thyroiditis, Grave's disease, Ankylosing Spondylitis Sjogrens Disease, CREST syndrome, Scleroderma, Rheumatic Disease, organ rejection, Primary Sclerosing Cholangitis, or sepsis.
103. The method of claim 96, wherein the cardiovascular disease comprises atherosclerosis, congestive heart failure, vulnerable plaque, stroke, ischemia, high blood pressure, stenosis, vessel occlusion or a thrombotic event.
104. The method of claim 96, wherein the neurological disease comprises Multiple Sclerosis (MS), Parkinson's Disease (PD), Alzheimer's Disease (AD), schizophrenia, bipolar disorder, depression, autism, Prion Disease, Pick's disease, dementia, Huntington disease (HD), Down's syndrome, cerebrovascular disease, Rasmussen's encephalitis, viral meningitis, neurospsychiatric systemic lupus erythematosus (NPSLE), amyotrophic lateral sclerosis, Creutzfeldt-Jacob disease, Gerstmann-Straussler-Scheinker disease, transmissible spongiform encephalopathy, ischemic reperfusion damage (e.g. stroke), brain trauma, microbial infection, or chronic fatigue syndrome.
105. The method of claim 96, wherein the pain comprises fibromyalgia, chronic neuropathic pain, or peripheral neuropathic pain.
106. The method of claim 96, wherein the infectious disease comprises a bacterial infection, viral infection, yeast infection, Whipple's Disease, Prion Disease, cirrhosis, methicillin-resistant Staphylococcus aureus, HIV, HCV, hepatitis, syphilis, meningitis, malaria, tuberculosis, influenza.
107. A kit comprising a reagent for carrying out the method of any of claims 79-106.
108. Use of a reagent for carrying out the method of any of claims 79-106.
109. The kit of claim 107 or use of claim 108, wherein the reagent comprises at least one of a primer configured to amplify a small RNA, a binding agent to Ago2, a reagent for isolating microvesicles, and any any useful combination thereof.
</claims>
</document>
